SCHEMBL40001

SCHEMBL40001

FC(F)(F)NCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
THRB P10828 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 4/20 0.46
CYP3A4 P08684 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PTPN1 P18031 1/20 0.44
PTPRZ1 P23471 1/20 0.44
ALOX12 P18054 2/20 0.43
ADH1B P00325 1/20 0.43
ADH1C P00326 1/20 0.43
ADH1A P07327 1/20 0.43
ADH7 P40394 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4708715 0.98 MAPT (0.50) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL3957337 0.79 IDO1 (0.43) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL105639 0.78 MAPT (0.45) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL1258399 0.76 L3MBTL1 (0.54) IDO1THRBMAPTCYP3A4ALDH1A1
SCHEMBL16357660 0.76 PTPN1 (0.36) PTPN1PTPRZ1ALDH1A1CA2HTT
SCHEMBL11624285 0.76 ADH1B (0.41) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL11624279 0.76 MEN1 (0.40) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL3166445 0.76 TAAR1 (0.47) IDO1MAOA
SCHEMBL31230181 0.75 IDO1 (0.48) IDO1MEN1KMT2ATHRBTDP1
SCHEMBL9482260 0.75 IDO1 (0.61) IDO1MEN1KMT2ATHRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094389-A Perovskite material, perovskite layer, preparation method of perovskite layer, perovskite solar cell and photovoltaic module 2026-05-26 CN claimed
CN-114420852-B Preparation method of pure-phase RP perovskite film 河北工业大学 2025-05-27 CN claimed
CN-114824092-B Solar cell based on quasi-two-dimensional perovskite and preparation method thereof 北京炎和科技有限公司 2025-04-18 CN claimed
CN-116217486-B Fluorescent compound and preparation method and application thereof 厦门大学 2024-05-14 CN claimed
CN-117866616-A Synthesis method of crown ether nested pyrenyl molecule 东南大学 2024-04-12 CN claimed
CN-116903544-A Preparation method of olanzapine and intermediate thereof 江苏丽源医药有限公司 2023-10-20 CN claimed
CN-116574058-A Lipid-droplet fluorescent probe and preparation method and application thereof 厦门大学 2023-08-11 CN claimed
CN-116367565-A Quasi two-dimensional perovskite nanocrystalline modified three-dimensional perovskite solar cell 河北工业大学 2023-06-30 CN claimed
CN-111704575-B Synthesis method of quinoline-2-thiocarboxamide compound under conditions of no catalyst and no additive 衡阳师范学院 2023-06-09 CN claimed
CN-116217486-A Fluorescent compound and preparation method and application thereof 厦门大学 2023-06-06 CN claimed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP claimed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 WO claimed
US-6376712-B2 REDUCTION OF THE CORRESPONDING OXIME COMPOUND CENTRAL GLASS COMPANY, LIMITED (JP) 2002-04-23 US claimed
US-6362372-B2 HYDROGENATION OF A TRIFLUOROBENZYLNITRILE BY HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA AND A CATALYST COMPRISING A PLATINUM GROUP ELEMENT; EXTREMELY HIGH YIELDS CENTRAL GLASS COMPANY, LIMITED (JP) 2002-03-26 US claimed
US-20020013500-A1 Process for producing trifluoromethylbenzylamines CENTRAL GLASS COMPANY, LIMITED (JP) 2002-01-31 US claimed
US-20020007086-A1 Process for producing trifluoromethylbenzylamines CENTRAL GLASS COMPANY, LIMITED (JP) 2002-01-17 US claimed
US-6331649-B1 REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID CENTRAL GLASS COMPANY, LIMITED (JP) 2001-12-18 US claimed
CN-1317006-A Antiparasitic artemisinin derivatives (endoperoxides) BAYER AG (DE) 2001-10-10 CN claimed
US-6175041-B1 HYDROGENATING A TRIFLUOROMETHYLBENZONITRILE WITH HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA, USING A RANEY CATALYST CENTRAL GLASS COMPANY, LIMITED (JP) 2001-01-16 US claimed
CN-1181069-A 5 -(4 -subst. -piperidinyl -1) -3 -aryl -pentanoic acid derivatives as tachykinin receptor antagonist ZENECA LTD (GB) 1998-05-06 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007086-A1 Process for producing trifluoromethylbenzylamines IDH1, INMT, TH IDO1 88/4885MEN1 1477/4885KMT2A 802/4885
US-20020013500-A1 Process for producing trifluoromethylbenzylamines MAOB, CYP2F1, AGL IDO1 49/4885MEN1 2111/4885KMT2A 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.